multimmune GmbH

delivering innovative cancer theranostics




With current statistics indicating that the lifetime risk of developing cancer is now 1 in 2, it is essential that approaches for diagnosing and treating cancer continue to be improved.

Although progress in the development of new cancer therapies for the majority of tumour entities progresses at a pace, key challenges in the management and treatment of aggressive disease remain. Another big challenge relates to the time and cost of drug development, and thereby the ability of the healthcare providers to afford the therapeutics that are developed. The identification of more ‘universal’ targeting structures that are present across different cancer entities will consolidate the costs of developing therapies during the pre-clinical and early clinical phases.

multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists' (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. This makes this form of Hsp70 an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics (theranostics).

multimmune is focussed on significantly improving the management and treatment of patients with cancer as quickly as possible, and is developing a number of patent-protected therapeutic interventions, drug targetting tools, diagnostic tools and imaging platforms that exploit its seminal discovery.....continue reading

Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone (ReportLinker, 2014). This is by far the fastest-growing segment of the industry.